sparsentan   Click here for help

GtoPdb Ligand ID: 8448

Synonyms: DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors) | BMS-346567 | compound 7 [PMID 15634011] | Filspari® | RE-021 | retrophin
Approved drug Immunopharmacology Ligand
sparsentan is an approved drug (FDA (2023))
Compound class: Synthetic organic
Comment: Sparsentan (RE-021) is a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1) [5-6]. Sparsentan combines the active moieties of the selective AT1 receptor antagonist irbesartan and a selective ETA receptor antagonist (see ligand 91 in [5]).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 12
Topological polar surface area 122.48
Molecular weight 592.27
XLogP 5.9
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2
Isomeric SMILES CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2
InChI InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
InChI Key WRFHGDPIDHPWIQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Sparsentan progressed to phase 3 clinical trial for evaluation as a potential treatment for focal segmental glomerulosclerosis (FSGS) [3]. FSGS is a rare glomerular disorder which results in proteinuria and progression to end-stage kidney disease (ESKD) over 5-10 years. The EMA issued orphan designation for the treatment of primary IgA nephropathy (IgAN) in January 2022 [2]. FDA approval for this indication was granted in February 2023 (under their accelerated approval program) [7]. The FDA's approval indicates sparsentan's use for patients with primary IgAN who are at high risk of rapid disease progression. Sparsentan is administered to reduce proteinuria in these patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Reduction of proteinuria in FSGS is regarded as being beneficial by slowing disease progression [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03493685 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Phase 3 Interventional Travere Therapeutics, Inc. 4
NCT01613118 Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis Phase 2 Interventional Travere Therapeutics, Inc. 8